{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:04:35Z","timestamp":1792674275941,"version":"4.5.0"},"reference-count":35,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:00:00Z","timestamp":1476921600000},"content-version":"vor","delay-in-days":73,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"name":"National Health Services in the counties of Copenhagen, Aarhus, Ringk\u00f8bing, Ribe, and Southern Jutland in Denmark"},{"DOI":"10.13039\/100007398","name":"Danish Council for Strategic Research;","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007398","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Danish Research Foundation for General Practice"},{"name":"Danish Centre for Evaluation and Health Technology Assessment"},{"name":"Diabetes Fund of the National Board of Health"},{"DOI":"10.13039\/100008392","name":"Danish Medical Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002739","name":"Aarhus University Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002739","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Foundation for the Study of Diabetes\/Pfizer for Research into Cardiovascular Disease Risk Reduction in Patients with Diabetes","award":["74550801"],"award-info":[{"award-number":["74550801"]}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:p>Hyperinsulinemia is an adaptive mechanism that enables the maintenance of normoglycemia in the presence of insulin resistance. We assessed whether glucagon is also involved in the adaptation to insulin resistance. A total of 1,437 individuals underwent an oral glucose tolerance test with measurements of circulating glucose, insulin, and glucagon concentrations at 0, 30 and 120 min. Early glucagon suppression was defined as suppression in the period from 0 to 30 min, and late glucagon suppression as 30 to 120 min after glucose intake. Insulin sensitivity was estimated by the validated insulin sensitivity index. Individuals with screen-detected diabetes had 30% higher fasting glucagon levels and diminished early glucagon suppression, but greater late glucagon suppression when compared with individuals with normal glucose tolerance (P \u2264 0.014). Higher insulin resistance was associated with higher fasting glucagon levels, less early glucagon suppression, and greater late glucagon suppression (P &amp;lt; 0.001). The relationship between insulin sensitivity and fasting glucagon concentrations was nonlinear (P &amp;lt; 0.001). In conclusion, increased fasting glucagon levels and delayed glucagon suppression, together with increased circulating insulin levels, develop in parallel with insulin resistance. Therefore, glucose maintenance during insulin resistance may depend not only on hyperinsulinemia but also on the ability to suppress glucagon early after glucose intake.<\/jats:p>","DOI":"10.2337\/db16-0240","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T22:33:13Z","timestamp":1470695593000},"page":"3473-3481","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":188,"title":["Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation"],"prefix":"10.2337","volume":"65","author":[{"given":"Kristine","family":"F\u00e6rch","sequence":"first","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"Vistisen","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pacini","sequence":"additional","affiliation":[{"name":"Metabolic Unit, Institute of Neurosciences, Istituto Di Neuroscienze-Consiglio Nazionale Delle Ricerche, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe S.","family":"Torekov","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna B.","family":"Johansen","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"},{"name":"The Danish Diabetes Academy, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Witte","sequence":"additional","affiliation":[{"name":"The Danish Diabetes Academy, Odense, Denmark"},{"name":"Section of General Practice, Institute of Public Health, University of Aarhus, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jonsson","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluf","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Hansen","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Lauritzen","sequence":"additional","affiliation":[{"name":"Section of General Practice, Institute of Public Health, University of Aarhus, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit E.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ahr\u00e9n","sequence":"additional","affiliation":[{"name":"Division of Medicine, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Juul","family":"Holst","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"key":"2022031211465758100_B1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.peptides.2015.03.011","article-title":"Glucagon\u2014early breakthroughs and recent discoveries","volume":"67","author":"Ahr\u00e9n","year":"2015","journal-title":"Peptides"},{"key":"2022031211465758100_B2","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031211465758100_B3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1172\/JCI106297","article-title":"Studies of pancreatic alpha cell function in normal and diabetic subjects","volume":"49","author":"Unger","year":"1970","journal-title":"J Clin Invest"},{"key":"2022031211465758100_B4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1210\/jcem-64-1-106","article-title":"Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus","volume":"64","author":"Reaven","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031211465758100_B5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00125-006-0566-z","article-title":"Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus","volume":"50","author":"Knop","year":"2007","journal-title":"Diabetologia"},{"key":"2022031211465758100_B6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00125-008-0951-x","article-title":"Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action","volume":"51","author":"F\u00e6rch","year":"2008","journal-title":"Diabetologia"},{"key":"2022031211465758100_B7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJM199201023260104","article-title":"Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance","volume":"326","author":"Mitrakou","year":"1992","journal-title":"N Engl J Med"},{"key":"2022031211465758100_B8","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/0026-0495(84)90089-1","article-title":"Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance","volume":"33","author":"Borghi","year":"1984","journal-title":"Metabolism"},{"key":"2022031211465758100_B9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00125-005-0056-8","article-title":"Glucagon secretion in relation to insulin sensitivity in healthy subjects","volume":"49","author":"Ahr\u00e9n","year":"2006","journal-title":"Diabetologia"},{"key":"2022031211465758100_B10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/diacare.23.5.650","article-title":"Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance","volume":"23","author":"Larsson","year":"2000","journal-title":"Diabetes Care"},{"key":"2022031211465758100_B11","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2337\/db07-0100","article-title":"Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?","volume":"56","author":"Knop","year":"2007","journal-title":"Diabetes"},{"key":"2022031211465758100_B12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00125-007-0598-z","article-title":"Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects","volume":"50","author":"Meier","year":"2007","journal-title":"Diabetologia"},{"key":"2022031211465758100_B13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1210\/er.2006-0007","article-title":"Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains","volume":"28","author":"Gromada","year":"2007","journal-title":"Endocr Rev"},{"key":"2022031211465758100_B14","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"2022031211465758100_B15","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2337\/db08-0958","article-title":"Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes","volume":"58","author":"Chia","year":"2009","journal-title":"Diabetes"},{"key":"2022031211465758100_B16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/eje.0.1500097","article-title":"Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies","volume":"150","author":"Ahr\u00e9n","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2022031211465758100_B17","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1186\/1471-2458-12-1078","article-title":"Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care","volume":"12","author":"Johansen","year":"2012","journal-title":"BMC Public Health"},{"key":"2022031211465758100_B18","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/sj.ijo.0801420","article-title":"The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening","volume":"24","author":"Lauritzen","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2022031211465758100_B19","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.2337\/db14-1751","article-title":"Glucagon-like peptide-1 (GLP-1) response to oral glucose is reduced in pre-diabetes, screen-detected type 2 diabetes and obesity, and influenced by sex: the ADDITION-PRO Study","volume":"64","author":"F\u00e6rch","year":"2015","journal-title":"Diabetes"},{"key":"2022031211465758100_B20","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00125-014-3283-z","article-title":"Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?","volume":"57","author":"Wewer Albrechtsen","year":"2014","journal-title":"Diabetologia"},{"key":"2022031211465758100_B21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2337\/db15-1541","article-title":"Evidence of extrapancreatic glucagon secretion in man","volume":"65","author":"Lund","year":"2016","journal-title":"Diabetes"},{"key":"2022031211465758100_B22","first-page":"359","article-title":"Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours","volume":"24","author":"Holst","year":"1983","journal-title":"Diabetologia"},{"key":"2022031211465758100_B23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diab.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans","volume":"43","author":"\u00d8rskov","year":"1994","journal-title":"Diabetes"},{"key":"2022031211465758100_B24","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1210\/jc.2011-0266","article-title":"Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans","volume":"96","author":"Lindgren","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031211465758100_B25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/jc.2015-3133","article-title":"Glucose-dependent insulinotropic polypeptide is associated with lower low-density lipoprotein but unhealthy fat distribution, independent of insulin: the ADDITION-PRO Study","volume":"101","author":"M\u00f8ller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031211465758100_B26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0168-8227(99)00116-3","article-title":"Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures","volume":"47","author":"Gutt","year":"2000","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031211465758100_B27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.mcna.2004.04.013","article-title":"Pathogenesis of type 2 diabetes mellitus","volume":"88","author":"DeFronzo","year":"2004","journal-title":"Med Clin North Am"},{"key":"2022031211465758100_B28","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diab.42.11.1663","article-title":"Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function","volume":"42","author":"Kahn","year":"1993","journal-title":"Diabetes"},{"key":"2022031211465758100_B29","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2337\/dc16-0351","article-title":"Roles of the Gut in Glucose Homeostasis","volume":"39","author":"Holst","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031211465758100_B30","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.2337\/dc13-0592","article-title":"Impact of glucose tolerance status, sex, and body size on glucose absorption patterns during OGTTs","volume":"36","author":"F\u00e6rch","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031211465758100_B31","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.2337\/dc12-1609","article-title":"Relationships between gastric emptying, postprandial glycemia, and incretin hormones","volume":"36","author":"Marathe","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031211465758100_B32","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1007\/s00125-007-0806-x","article-title":"Association of fasting glucagon and proinsulin concentrations with insulin resistance","volume":"50","author":"Ferrannini","year":"2007","journal-title":"Diabetologia"},{"key":"2022031211465758100_B33","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.2337\/db13-1878","article-title":"Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young\u2014type 2 and type 3","volume":"63","author":"\u00d8stoft","year":"2014","journal-title":"Diabetes"},{"key":"2022031211465758100_B34","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00125-008-1149-y","article-title":"Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas","volume":"51","author":"de Heer","year":"2008","journal-title":"Diabetologia"},{"key":"2022031211465758100_B35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/bj2070381","article-title":"Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin","volume":"207","author":"Holst","year":"1982","journal-title":"Biochem J"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/diabetes.diabetesjournals.org\/syndication\/doi\/10.2337\/db16-0240","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/65\/11\/3473\/417122\/db160240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/65\/11\/3473\/417122\/db160240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:30:04Z","timestamp":1667392204000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/65\/11\/3473\/17158\/Insulin-Resistance-Is-Accompanied-by-Increased"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,8,8]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db16-0240","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]}}}